Italia markets closed

Cabaletta Bio, Inc. (CABA)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
12,38+0,88 (+7,65%)
Alla chiusura: 4:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente11,50
Aperto11,55
Denaro11,00 x 800
Lettera12,35 x 1000
Min-Max giorno11,27 - 12,64
Intervallo di 52 settimane7,00 - 16,38
Volume164.556
Media Volume169.452
Capitalizzazione309,163M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-1,62
Prossima data utili08 nov 2021 - 12 nov 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A22,60
  • GlobeNewswire

    Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

    PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. “We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will comp

  • GlobeNewswire

    Cabaletta Bio to Participate in Upcoming Investor Conferences in September

    PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September: Morgan Stanley 19th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fire

  • GlobeNewswire

    Cabaletta Bio Reports Clinical Data from the Second Dose Cohort in DesCAARTes™ Trial in Patients with mPV

    – No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort – – DSG3-CAART persistence observed in all three patients in the second dose cohort during the 28 days following infusion – – Dosing initiated in third cohort at 500 million cells, with biologic activity data from the first two dosing cohorts and third cohort safety data anticipated in 4Q21 – PHILADELPHIA, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cabalett